Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118644919&loc=SL5834089-161433

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 808
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434

+ Details

Name:	us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbrv_SinovantSciencesLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_VestingAxis=nbrv_VestingSubjectToUnitedStatesFoodAndDrugAdministrationApprovalOfNewDrugApplicationXenletaInMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nbrv_LicenseInitialPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=nbrv_SunovionPharmaceuticsCanadaInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nbrv_ContingentConsiderationDeemedProbableToBeMetAndReceivedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=nbrv_ClinicalTrialApplicationSubmissionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nbrv_ResearchPremiumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=nbrv_GovernmentGrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue
Revenue accounted for under Topic 606		$ 6,920	$ 461	$ 9,148	$ 8,859
Collaboration revenue
Revenue
Revenue accounted for under Topic 606		5,051		6,051	6,500
Collaboration revenue \| License Agreement \| Sinovant Sciences, LTD \| Vesting subject to FDA approval of NDA for XENLETA
Revenue
Revenue accounted for under Topic 606		5,000		5,000
Collaboration revenue - Upfront payment
Revenue
Revenue accounted for under Topic 606		1,445		1,445
Collaboration revenue - Upfront payment \| License Agreement \| Sinovant Sciences, LTD
Revenue
Revenue accounted for under Topic 606	$ 5,000				5,000
Collaboration revenue - Upfront payment \| License Agreement \| Sunovion Pharmaceutics Canada, Inc.
Revenue
Revenue not accounted for under Topic 606				1,000
Collaboration revenue - Variable consideration
Revenue
Revenue accounted for under Topic 606		5,051		6,051	6,500
Collaboration revenue - Variable consideration \| License Agreement \| Clinical trial application submission \| Sinovant Sciences, LTD
Revenue
Revenue accounted for under Topic 606					1,500
Research premium
Revenue
Revenue accounted for under Topic 606		$ 424	427	1,168	1,907
Government grants
Revenue
Revenue accounted for under Topic 606			$ 34	$ 484	$ 452